The speed, flexibility and strong risk-benefit ratio of virtual clinical trials could all be highlighted in the assessment of potential Covid-19 treatments, according to industry bosses.
Dr Calvin H Knowlton, chairman and CEO of US healthtech firm TRHC (Tabula Rasa HealthCare), believes the use of new technologies such as AI in predicting medication safety could provide “a win for everyone” by keeping patients healthier and safer — even after the pandemic has subsided.
TRHC recently announced a partnership with Washington-based health plan provider Regence to virtually trial several different Covid-19 drug candidates, and assess the risk of adverse drug events (ADEs) in each.
Matt Hafermann, a clinical pharmacist in case management at Regence, said: “As Covid-19 has shown us, when novel viruses or diseases are discovered, having another method to pair with conventional clinical trials will help accelerate the scientific knowledge for treatment and prevention of diseases.
“Due to the global impact of Covid-19, collaboration between all sectors of healthcare is essential in identifying, assessing and developing therapies to minimise the virus’ impact.
“Through this partnership, we can help contribute to a long-term recovery plan that prioritises health and safety, while sharing results that aid other researchers working on strategies to combat Covid-19.”
